跳至主要内容
临床试验/NCT01540019
NCT01540019Unknown1 期

Guarana (Paullinia Cupana) for Anorexia Related to Cancer

Faculdade de Medicina do ABC1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
入组人数
35
试验地点
1
主要终点
weight

研究概览

简要总结

Denutrition, lost of weight and anorexia are present in many oncologic patients at any time of the disease. Anorexia is the spontaneous loss of appetite and many changes in the metabolism are made in this case, leading to this syndrome called anorexia-cachexia, that includes changes in the tumoral response and inflammatory pathways. The guaraná (Paullinia cupana) is originally from Brazil and Venezuela and has been used culturally for headaches, muscle pains, depression and others. As it has shown a good response and tolerability for fatigue, the investigators decide to try guaraná for anorexia. Patients will receive guaraná as capsules of 50 mg twice daily, for 4 weeks, and will be weighted and respond questionaries about quality of life.

详细描述

Patients 18 years and older, diagnosed with any cancer, that is losing weight and have anorexia will be selected. They must have normal levels of creatinine, thyroid evaluation and hepatic function. If they are taking corticosteroid, they must keep losing weight and refer anorexia, as well as if they are on treatment with chemotherapy.

Patients will receive 50mg of the guaraná twice daily for 4 weeks. Every week will be an evaluation of the weight, level of appetite and answer 2 questionaries of quality of life and level of symptoms (FACT-G and MDASI).

This is a fase II study, open-label, no randomized, with two steps following ¨two stages of Simon¨ model. First step 18 patients will be included and if there are 3 good responses second step will follow, including 17 more patients. Response will be considered if there is at least 5% of gain in the weight.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adults (18 years old and older)
  • palliative care or oncologic treatment
  • loss of weight

排除标准

  • gastrointestinal obstruction
  • blood pressure not controlled
  • diabetes not treated

研究组 & 干预措施

Paullinea cupana

Experimental

50mg of Paullinia cupana as capsule, twice daily

干预措施: Paullinia cupana (Drug)

结局指标

主要结局

weight

时间窗: eight weeks

Patients will considered to respond to guaraná if the gain 5% or more of his inicial weight during the treatment period

次要结局

  • quality of life(eight weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Felipe Melo Cruz

MsC

Faculdade de Medicina do ABC

研究点 (1)

Loading locations...

相似试验